Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

As regional vice president for Northern Europe & Australia, Simon Lem led the digital launch of Vertex Pharma’s novel cystic fibrosis drug Kaftrio. ... UK’s opportunity for change.

Ten people have been effectively cured of their type 1 diabetes after a breakthrough infusion of a new treatment on the path ...

The first-ever CRISPR-based gene-editing therapy has been approved for marketing in the UK for inherited blood disorders sickle cell disease (SCD) and transfusion-dependent beta thalassaemia (TDT ...

Diabetes affects many people in the world, type 1 diabetes being a condition that can affect anyone, causing them to be on ...

Discover how personalized medicine uses genetics and data to create tailored treatments, improving outcomes in cancer, rare diseases, and more. Explore its future in healthcare.

Google Gemini is making waves in 2025 with advanced AI tools built to support entrepreneurs and small business owners. This ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers. Did ...